Over 20 years of clinical research with advanced therapy medicinal products based on Cultured Mesenchymal Cells (CMC)

The progress of ITRT has been made possible thanks to the clinical trials conducted, which have enabled the development of advanced therapy medicinal products regulated by the Health Authorities.

All clinical trials involving Mesenchymal Cells have been carried out following prior approval and under the supervision of the corresponding Clinical Research Ethics Committees (CEIm), and with authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS). In compliance with the legal requirement in force since January 1st, 2013, all trials were registered in the international databases EudraCT and ClinicalTrials.gov prior to their initiation.

Clinical Trials with Cultured Mesenchymal Cells (CMC)

Clinical Trial in Osteoarthritis with autologous Cultured Mesenchymal Cells (CMC), Valladolid (MSV)

Clinical Trial in hypotrophic Pseudoarthrosis (TRC) with autologous Cultured Mesenchymal Cells (CMC) from Aastrom Biosciences

Clinical Trial in Osteoarthritis with allogeneic Cultured Mesenchymal Cells (CMC), Valladolid (MSV)

Clinical Trial in Osteonecrosis of the femoral head with autologous Cultured Mesenchymal Cells (CMC) from Aastrom Biosciences

Clinical Trial in Lumbar degenerative disc disease with autologous Cultured Mesenchymal Cells (CMC), Valladolid (MSV)

Clinical Trial in Lumbar degenerative disc disease with allogeneic Cultured Mesenchymal Cells (CMC), Montpellier (RESPINE)

Clinical Trial in non-hypertrophic Pseudoarthrosis with autologous Cultured Mesenchymal Cells (CMC) from Aastrom Biosciences

Clinical Trial in patellar tendon Tendinopathy with autologous Cultured Mesenchymal Cells (CMC), Valladolid (MSV)

Clinical Trial in severe maxillary Edentulism with autologous Cultured Mesenchymal Cells (CMC) from Aastrom Biosciences

Clinical Trial in atrophic Pseudoarthrosis with autologous Cultured Mesenchymal Cells (CMC) from HC-SVT-1001

Clinical Trial in Osteoarthritis with autologous Cultured Mesenchymal Cells (CMC) from Xcel-m-condro-alpha

Clinical Trial in Xerostomia with autologous Cultured Mesenchymal Cells (CMC), Valladolid (MSV)

Clinical Tial in Osteoarthritis with cryopreserved Cultured Mesenchymal Cells (CMC) from MSV-crio

Preclinical Studies with Cultured Mesenchymal Cells (CMC)

Study in equine Osteoarthritis with Cultured Mesenchymal Cells (CMC)

Study in ovine Osteoarthritis with Cultured Mesenchymal Cells (CMC)

Study in ovine Nerve regeneration with Cultured Mesenchymal Cells (CMC)

Clinical Trials and Studies with Platelet-Rich Plasma (PRP)

Study in Osteoarthritis. Treatment with PRP. ITRT-Teknon (PRGF-BTI)

Clinical Trial in Muscle injuries (“tennis leg”). Treatment with PRP. ITRT (PRP)

Clinical Trials and preclinical Studies with PRP

Study in equine Osteoarthritis with Platelet-Rich Plasma (PRP)

Study in equine Tendinopathy with Platelet-Rich Plasma (PRP)

Study in canine and porcine Myocardium with Platelet-Rich Plasma (PRP)

Validated scientific evidence regulated by the AEMPS in advanced therapy medicinal products with CMC.

Through 15 clinical trials, ITRT has investigated advanced therapy medicinal products based on Cultured Mesenchymal Cells (CMC) across a wide range of pathologies: tendinopathies, intervertebral disc degeneration, osteoarthritis, pseudoarthrosis, osteonecrosis, maxillofacial surgery, and muscle injuries, among others.

This ongoing effort has led to the development of a solid body of scientific evidence, reinforcing biomedical knowledge and consolidating a regulated and safe framework towards a new era of medicine.